111 related articles for article (PubMed ID: 25044534)
1. Discovery of natural products possessing selective eukaryotic readthrough activity: 3-epi-deoxynegamycin and its leucine adduct.
Taguchi A; Hamada K; Kotake M; Shiozuka M; Nakaminami H; Pillaiyar T; Takayama K; Yakushiji F; Noguchi N; Usui T; Matsuda R; Hayashi Y
ChemMedChem; 2014 Oct; 9(10):2233-7. PubMed ID: 25044534
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutics overcoming nonsense mutation-associated genetic diseases: medicinal chemistry of negamycin.
Taguchi A; Hamada K; Hayashi Y
J Antibiot (Tokyo); 2018 Feb; 71(2):205-214. PubMed ID: 28951602
[TBL] [Abstract][Full Text] [Related]
3. Structure-Activity Relationship Study of Leucyl-3-
Taguchi A; Hamada K; Shiozuka M; Kobayashi M; Murakami S; Takayama K; Taniguchi A; Usui T; Matsuda R; Hayashi Y
ACS Med Chem Lett; 2017 Oct; 8(10):1060-1065. PubMed ID: 29057051
[TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Relationship Studies of 3-epi-Deoxynegamycin Derivatives as Potent Readthrough Drug Candidates.
Hamada K; Taguchi A; Kotake M; Aita S; Murakami S; Takayama K; Yakushiji F; Hayashi Y
ACS Med Chem Lett; 2015 Jun; 6(6):689-94. PubMed ID: 26101575
[TBL] [Abstract][Full Text] [Related]
5. New Negamycin-Based Potent Readthrough Derivative Effective against TGA-Type Nonsense Mutations.
Hamada K; Omura N; Taguchi A; Baradaran-Heravi A; Kotake M; Arai M; Takayama K; Taniguchi A; Roberge M; Hayashi Y
ACS Med Chem Lett; 2019 Oct; 10(10):1450-1456. PubMed ID: 31620232
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes.
Allamand V; Bidou L; Arakawa M; Floquet C; Shiozuka M; Paturneau-Jouas M; Gartioux C; Butler-Browne GS; Mouly V; Rousset JP; Matsuda R; Ikeda D; Guicheney P
J Gene Med; 2008 Feb; 10(2):217-24. PubMed ID: 18074402
[TBL] [Abstract][Full Text] [Related]
7. Development of Conformationally Restricted Negamycin Derivatives for Potent Readthrough Activity.
Omura N; Taguchi A; Kuwahara T; Hamada K; Watanabe M; Nakakuki M; Konno S; Takayama K; Taniguchi A; Nomura T; Shuto S; Hayashi Y
ACS Med Chem Lett; 2023 Dec; 14(12):1807-1814. PubMed ID: 38116427
[TBL] [Abstract][Full Text] [Related]
8. Conformationally restricted analogs of deoxynegamycin.
Raju B; Anandan S; Gu S; Herradura P; O'Dowd H; Kim B; Gomez M; Hackbarth C; Wu C; Wang W; Yuan Z; White R; Trias J; Patel DV
Bioorg Med Chem Lett; 2004 Jun; 14(12):3103-7. PubMed ID: 15149653
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of taxlllaids A-G; natural products from Xenorhabdus indica.
Kronenwerth M; Bozhüyük KA; Kahnt AS; Steinhilber D; Gaudriault S; Kaiser M; Bode HB
Chemistry; 2014 Dec; 20(52):17478-87. PubMed ID: 25351611
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical therapies to recode nonsense mutations in inherited diseases.
Lee HL; Dougherty JP
Pharmacol Ther; 2012 Nov; 136(2):227-66. PubMed ID: 22820013
[TBL] [Abstract][Full Text] [Related]
11. Update 1 of: α,β-Diamino acids: biological significance and synthetic approaches.
Viso A; Fernández de la Pradilla R; Tortosa M; García A; Flores A
Chem Rev; 2011 Feb; 111(2):PR1-42. PubMed ID: 21306179
[No Abstract] [Full Text] [Related]
12. Feasibility of nonsense mutation readthrough as a novel therapeutical approach in propionic acidemia.
Sánchez-Alcudia R; Pérez B; Ugarte M; Desviat LR
Hum Mutat; 2012 Jun; 33(6):973-80. PubMed ID: 22334403
[TBL] [Abstract][Full Text] [Related]
13. Empirical antibacterial drug discovery--foundation in natural products.
Singh SB; Barrett JF
Biochem Pharmacol; 2006 Mar; 71(7):1006-15. PubMed ID: 16412984
[TBL] [Abstract][Full Text] [Related]
14. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy.
Howard MT; Shirts BH; Petros LM; Flanigan KM; Gesteland RF; Atkins JF
Ann Neurol; 2000 Aug; 48(2):164-9. PubMed ID: 10939566
[TBL] [Abstract][Full Text] [Related]
15. Cancer syndromes and therapy by stop-codon readthrough.
Bordeira-Carriço R; Pêgo AP; Santos M; Oliveira C
Trends Mol Med; 2012 Nov; 18(11):667-78. PubMed ID: 23044248
[TBL] [Abstract][Full Text] [Related]
16. Marine actinobacteria: an important source of bioactive natural products.
Manivasagan P; Kang KH; Sivakumar K; Li-Chan EC; Oh HM; Kim SK
Environ Toxicol Pharmacol; 2014 Jul; 38(1):172-88. PubMed ID: 24959957
[TBL] [Abstract][Full Text] [Related]
17. Natural products as starting points for the synthesis of complex and diverse compounds.
Morrison KC; Hergenrother PJ
Nat Prod Rep; 2014 Jan; 31(1):6-14. PubMed ID: 24219884
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity of some natural products against bacteria expressing a multidrug-resistant phenotype.
Kuete V; Alibert-Franco S; Eyong KO; Ngameni B; Folefoc GN; Nguemeving JR; Tangmouo JG; Fotso GW; Komguem J; Ouahouo BM; Bolla JM; Chevalier J; Ngadjui BT; Nkengfack AE; Pagès JM
Int J Antimicrob Agents; 2011 Feb; 37(2):156-61. PubMed ID: 21163632
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial natural products: an update on future antibiotic drug candidates.
Saleem M; Nazir M; Ali MS; Hussain H; Lee YS; Riaz N; Jabbar A
Nat Prod Rep; 2010 Feb; 27(2):238-54. PubMed ID: 20111803
[TBL] [Abstract][Full Text] [Related]
20. Translational readthrough induction of pathogenic nonsense mutations.
Kellermayer R
Eur J Med Genet; 2006; 49(6):445-50. PubMed ID: 16740421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
